Longeveron Inc.

Greetings and welcome to the Longeviron 2025 Q2 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star, then zero, on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Derek Cole, Investor Relations. Thank you. You may begin.

Thank you, operator. Good afternoon, everyone, and thank you for joining us today to review Longeviron's 2025 second quarter financial results and business update. After the U.S. markets closed today, we issued a press release with financial results for Q2 2025, which can be found under the investor section of the Longeviron website. On the call today are Wael Hashad, chief executive officer, Dr. Joshua Hare, co-founder, chief science officer, and chairman of the board, Natalia Agafanova, Chief Medical Officer, Lisa Locklear, Chief Financial Officer, and Devin Blass, Chief Technology Officer. As a reminder, during this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in the company's filings with the Securities and Exchange Commission, which we encourage you to review. Following the company's prepared remarks, we will open the call to questions from covering analysts. With that, let me hand the call over to Wael Hashad, Chief Executive Officer. Wael.

Thank you, Derek. Thank you all for joining us today.